

August 4, 2025

MEDIPAL HOLDINGS CORPORATION  
Representative: Shuichi Watanabe, Representative Director, President and CEO  
Code number: 7459 (Prime Market, Tokyo Stock Exchange)  
Contact: Yuji Sakon,  
Managing Director, General Manager of Administration Division  
Tel: +81-3-3517-5171

## Notice Regarding Progress of Acquisition of Treasury Stock

MEDIPAL HOLDINGS CORPORATION has implemented the acquisition of treasury stock based on the provisions of the Articles of Incorporation pursuant to Article 459, Paragraph 1 of the Companies Act, which was resolved at the Board of Directors meeting held on May 13, 2025.

Details follow below.

- |                                      |   |
|--------------------------------------|---|
| (1) Class of stock acquired          | Common stock                                  |
| (2) Total number of shares acquired: | 607,500 shares (on an Execution basis)        |
| (3) Total amount acquired            | JPY 1,459,305,486                             |
| (4) Period of acquisition            | From July 1, 2025 to July 31, 2025            |
| (5) Method of acquisition            | Market purchasing on the Tokyo Stock Exchange |

### Reference

#### 1. Details of the resolution at the Board of Directors meeting held on May 13, 2025

(1)	Class of stock to be acquired	Common stock
(2)	Total number of shares to be acquired	Up to 4,000,000 shares (1.9% of the total number of common stock issued (excluding treasury stock))
(3)	Total acquisition cost	Up to 8 billion yen
(4)	Period of acquisition	From May 14, 2025 to October 31, 2025
(5)	Method of acquisition	Market purchasing on the Tokyo Stock Exchange

#### 2. Total number of shares and amount acquired pursuant to the above resolution as of July 31, 2025

(1)	Total number of shares acquired	1,687,900 shares (on an Execution basis)
(2)	Total amount acquired	JPY 3,942,231,425

# # #

The English version of this document is a translation of the Japanese original and is provided for information purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. In the event of any inconsistency or conflict between the English version and the Japanese original, the Japanese original shall prevail.